Sclerosis: all 3,103 studies
Page 32 of 32. Open to participants first (314), then studies with results posted, then the rest; newest registration first within each.
- Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)CompletedNCT00001781Phase 2
- A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) PatientsCompletedNCT00001669Phase 2
- Assessment of Patients With Multiple Sclerosis (MS)CompletedNCT00001156